Solid IO is a healthcare startup focused on transforming cancer care through advanced organ-on-chip technology. Their tumor-on-chip platform replicates the tumor microenvironment, providing real-time, patient-specific insights that enable oncologists to make informed treatment decisions. By bridging the gap between research and clinical applications, Solid IO aims to enhance precision in oncology, reduce the trial-and-error nature of current treatments, and integrate early-stage drug development with predictive analytics. The company’s technology supports researchers, clinicians, and pharmaceutical entities in optimizing treatment strategies and accelerating the advancement of immunotherapy and tailored therapies for cancer patients.